Opinion statement
Fetal arrhythmia is a common reason for referral to fetal cardiology. Fetal supraventricular tachycardia can be subdivided into several groups with the most common being re-entrant supraventricular tachycardia and atrial flutter. Fetal tachycardia can lead to hydrops fetalis, which increases the risk of fetal demise, perinatal morbidities, and premature delivery. The diagnosis of fetal tachycardia can be a challenge as a traditional electrocardiogram cannot be completed on a fetus, and other methods must be used by fetal echocardiogram. Several retrospective studies have been completed to determine the best treatment; however, there continues to be no consensus on the best option. Digoxin, flecainide, and sotalol are commonly used and have favorable results depending on gestational age, fetal well-being, and presence of hydrops. Treatment in a timely manner can convert supraventricular tachycardia to a normal fetal heart rate, and hydrops can resolve with delivery at term if the proper medications are used.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
Bianchi DW, Crombleholme TM, D’Alton ME, Malone FD. “Tachyarrhythmias.” Fetology: diagnosis & management of the fetal patient. New York: McGraw-Hill, Medical Pub. Division; 2000. p. 313–9. Print.
Hornberger LK, Sahn DJ. Rhythm abrnormalities of the fetus. Heart. 2007;93:1294–300.
• Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014;129:2183–242. This statement is a great reference for all of fetal cardiology. It describes not only fetal arrhythmia and treatment choices but describes different types of heart disease and how to treat and follow/manage patients.
Jaeggi E. Electrophysiology for the perinatologist. In: Yagel S, Silverman N, Gembruch U, editors. Fetal cardiology: embryology, genetics, physiology, echocardiographic evaluation, diagnosis and perinatal management of cardiac diseases. 2nd ed. New York: Informa Healthcare USA; 2009. p. 435–48.
Gembruch U. Fetal tachyarrhtyhmia. In: Yagel S, Silverman N, Gembruch U, editors. Fetal cardiology: embryology, genetics, physiology, echocardiographic evaluation, diagnosis and perinatal management of cardiac diseases. 2nd ed. New York: Informa Healthcare USA; 2009. p. 461–81.
Jaeggi E, Ohman A. Fetal and neonatal arrhythmias. Clin Perinatol. 2016;43:99–112.
Matta M, Cuneo B. Doppler echocardiography for managing fetal cardiac arrhythmia. Clin Obstet Gynecol. 2010;53(4):899–914.
Wacker-Gussmann A, Strasburger JF, Cuneo BF, Wakai RT. Diagnosis and treatment of fetal arrhythmia. Am J Perinatol. 2014;31(7):617–28.
Jaeggi E, Fouron JC, Fournier A, et al. Ventriculo-atrial time interval measured on M mode echocardiography: a determining element, diagnosis, treatment, and prognosis of fetal supraventricular tachycardia. Heart. 1998;79(6):582–7.
Fouron JC. Fetal arrhythmias: the Saint-Justine Hospital Experience. Prenat Diagn. 2004;24(13):1068–80.
Nii M, Hamilton RM, Fenwick L, et al. Assessment of fetal atrioventricular time intervals by tissue Doppler and pulse Doppler echocardiography: normal values and correlation with fetal electrocardiography. Heart. 2006;92(12):1831–7.
Cuneo BF, Strasburger JF, Yu S, et al. In utero diagnosis of long QT syndrome by magnetocardiograpy. Circulation. 2013;128(20):2183–91.
Jaeggi E, Carvalho J, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation. 2011;124:1747–54.
Cuneo BF. Treatment of fetal tachycardia. Heart Rhythm. 2008;5(8):1216–8.
Ebenroth ES, Cordes TM, Darragh RK. Second-line treatment of fetal supraventricular tachycardia using flecainide acetate. Pediatr Cadiol. 2001;22:283–487.
Van Engelen AD, Weijtens O, Brenner JI. Management outcome and follow up of fetal tachycardia. J Am Coll Cardiol. 1994;24:1371–5.
Oudijk MA, Michon MM, Kleinman CS, et al. Sotalol in the treatment of fetal dysrhythmias. Circulation. 2000;101:2721–6.
• Strizek B, Berg C, Gottschalk I, et al. High dose flecainide is the most effective treatment of fetal supraventricular tachycardia. Heart Rhythm. 2016;13(16):1283–8. Recent article suggesting flecianide is the best first line treatment for fetal supraventricular tachycardia.
Allan LD, Chita SK, Sharland GK, et al. Flecainide in the treatment of fetal tachycardia. Br Heart J. 1991;65:46–8.
Strasburger J, Cuneo B, Michon M, Gottiener N, et al. Amiodarone therapy for drug-refractory fetal tachycardia. Circulation. 2004;109:375–9.
Younis JS, Granat M. Insufficient transplacental digoxin transfer in severe hydrops fetalis. Am J Obstet Gynecol. 1987;157:1268–9.
Parilla BV, Strasburger JF, Socol ML. Fetal supraventricular tachycardia complicated by hydrops fetalis: a role for direct fetal intramuscular therapy. Am J Perinatol. 1996;13:483–6.
Bourget P, Pons JC, Delouis C, Fermont L, et al. Flecainide distribution, transplacental passage, and accumulation in the amniotic fluid during the third trimester of pregnancy. Ann Pharmacother. 1994;28:1031–4.
Ghidini A, Sepulveda W, Lockwood CJ, et al. Complications of fetal blood sampling. Am J Obstet Gynecol. 1993;168:1339–44.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The author declares that she has no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Pediatric Congenital Heart Disease
Rights and permissions
About this article
Cite this article
Zoeller, B.B. Treatment of Fetal Supraventricular Tachycardia. Curr Treat Options Cardio Med 19, 7 (2017). https://doi.org/10.1007/s11936-017-0506-x
Published:
DOI: https://doi.org/10.1007/s11936-017-0506-x